Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
NCT04005170Phase 2Completed
- Sponsor
- Mianxi Biopharma
- Start
- Jun 2019
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Mianxi Biopharma. Started Jun 2019; status: completed.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04005170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04005170.